Clinical Studies
Clinical Studies
Search
1948-1990: Going global
The Boehringer Ingelheim history from 1948-1990, with milestones
Swine
Swine
Ruminants
Ruminants
Skin Diseases
Skin Diseases
Trends & Insights
Trends & Insights
Animal Health Innovation
Animal Health Innovation
Human Health Innovation
Human Health Innovation
Science & Innovation
Science & Innovation
Retinal Diseases
Retinal Diseases
Media & Insights | Bioxcellence
Stay updated with BioXcellence Media & Insights. Explore the latest industry trends & news in global biopharmaceutical contract manufacturing. Don't miss out!
Sustainable Development
Sustainable Development
Heidelberg Transforming Science Day 2025
The Heidelberg Transforming Science Day profiles what makes our innovation different including our ground-breaking research and our diverse pipeline.
Fostering Science
Fostering Science
Our Twitter Community Guidelines
Our Twitter Community Guidelines
Veterinary Public Health
Veterinary Public Health
Board of Managing Directors
Board of Managing Directors Boehringer Ingelheim
Partnering Culture
Partnering Culture
Animal Health Partnering Contacts
Partnership and diversity of thought are powerful drivers of innovation. If you have a project you would like to discuss please reach out to us.
We’re All In
Watch our video to learn about our approach to innovation and partnerships
“Rapid progress towards clinical candidates”
Boehringer Ingelheim forms a joint venture to create the next generation of antimicrobials.
Chronic kidney disease is a silent killer
Living with chronic kidney disease can have drastic impacts on a patient and their family’s life. A patient and her caregiver share their story on managing it.
Positive results Diabetic Macular Ischemia treatment
HORNBILL Phase I/II study shows positive results for potentially first ever Diabetic Macular Ischemia treatment
DCRI-collaboration-empact-mi
Collaboration with Duke Clinical Research Institute on EMPACT-MI trial, which will assess outcomes in people who have had a myocardial infarction
empulse-trial-benefit-acute-heart-failure
Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial